Clinical Trial Update: Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial update discusses concurrent ipilimumab with stereotactic ablative radiation therapy for oligometastatic, unresectable melanoma; current status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: Wolfram Samlowski | Conditions: Melanoma | Phase 2 | Status: UNKNOWN